A patient arrives with a screenshot from a Seoul clinic and asks for Rejuran®. The next has read about Profhilo® at a London practice. The category they are describing is real, and in the United States it currently consists of exactly one approved product.
Skin boosters are the cleanest case of Korean and European injectable practice reaching American consultation rooms ahead of American approval. Answering well means holding two things apart: the category logic — skin quality rather than volume and structure — and the availability picture, which is nothing like what the patient read. Both sit inside the wider question of how K-beauty is influencing U.S. aesthetic medicine.
The only skin booster with U.S. approval
SKINVIVE™ by Juvéderm® is the single FDA-approved injectable in this category. FDA approved it on May 11, 2023 as a panel-track supplement (P110033/S059) to the Juvéderm® Voluma XC premarket approval, and the indication reads: intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21. The approved endpoint is smoothness and the approved plane is intradermal, neither of which is what a volumizing filler is approved to do.
A second indication followed on June 11, 2026, when FDA approved a further panel-track supplement (P110033/S099) adding the neck. The combined indication now covers intradermal injection to improve skin smoothness of the cheeks and intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance, in adults over 21; Allergan Aesthetics announced it on June 16, 2026. Two cautions: the neck pivotal figures in trade coverage come from the company announcement, not a published FDA Summary of Safety and Effectiveness Data, and the neck indication permits a different plane than the cheek one, making it a different technique.
The product is a BDDE-crosslinked hyaluronic acid gel formulated to 12 mg/mL with 0.3% w/w lidocaine. The label describes an intradermal microdroplet technique and instructs aspiration before injection; volumes, droplet spacing and needle selection are label and hands-on training matters.
Skin quality versus volume: two different targets
A 2021 global Delphi consensus of ten dermatologists and aesthetic physicians — Goldie and colleagues, “Skin Quality – A Holistic 360° View: Consensus Results,” Clinical, Cosmetic and Investigational Dermatology 2021;14:643–654, PMID 34163203 — concluded that skin quality can be described across all ethnicities by four emergent perceptual categories: skin tone evenness, skin surface evenness, skin firmness and skin glow. The panel spanned eight countries, with a strong-consensus threshold above 95% agreement.
None of those four is what a syringe of high-G′ gel is built to deliver, and they are the parameters sitting under the consumer language patients use when they ask about glass skin and what it means clinically. A booster aims at surface evenness and glow; a volumizer aims at projection and contour.
Cadence, consent and photography
A volumizing filler has a structural endpoint the patient sees in the mirror before leaving; a booster does not, which changes three things in the chart. Cadence: a treated-and-maintained service, discussed as a plan rather than an event. Consent: the expected injection-site response, and improvement measured in texture rather than contour. Photography: subtle surface change is invisible in casual lighting, so standardized, repeatable images under identical conditions are the only honest way to judge it.
Rheology, crosslinking and injection plane
Fundarò and colleagues, writing on hyaluronic acid filler rheology in International Journal of Molecular Sciences (2022;23(18):10518, PMID 36142430), put the mechanical distinction plainly: the higher the G′, the higher the elasticity and resistance to deformation, and ultimately the greater the capacity to restore soft-tissue volume. Volumizers are built to resist deformation; boosters are built to distribute.
Rho and colleagues’ review in Archives of Plastic Surgery (2024;51(6):528–541, PMID 39544509) describes skin boosters as delivered by an intradermal multi-injection method, and makes the point that plane is mechanism: subdermal injection, they note, only replaced fluid volume without improving skin texture. They put the working hyaluronic acid range for skin-quality products at roughly 12 to 20 mg/mL, and observe that intradermal placement requires less crosslinked gels, smaller particle sizes or lower concentrations.
The cleanest contrast sits inside the same premarket approval: Juvéderm® Voluma XC, approved under P110033 on October 22, 2013, is indicated for deep subcutaneous and/or supraperiosteal injection for cheek augmentation to correct age-related volume deficit in the midface in adults over 21. Same manufacturer, same PMA number, same region — opposite plane and goal.
| Attribute | Skin booster | Volumizing filler |
|---|---|---|
| Primary goal | Skin quality: surface evenness, fine lines, hydration, glow | Volume and structural support |
| Typical plane | Intradermal (the neck indication also permits subdermal) | Deep subcutaneous and/or supraperiosteal |
| Crosslinking and rheology | Lower concentration, less crosslinked, lower G′ | Highly crosslinked, high G′, resists deformation |
| What it changes | How the skin surface reflects light and reads on close inspection | Projection, contour, midface volume deficit |
| Treatment cadence | Planned series with maintenance; benefit measured over months | Treated to a contour endpoint, reassessed at longer intervals |
Skin boosters are not collagen biostimulators
Providers blur this distinction constantly, and it matters: the two classes fail differently. A hyaluronic acid booster is a hydrophilic gel placed intradermally; what it does, it does while it is present. A collagen biostimulator — poly-L-lactic acid as Sculptra®, calcium hydroxylapatite as Radiesse® — is placed subcutaneously to provoke a host collagen response over months. Empire covers that comparison in biostimulator injections compared with fillers and the underlying biology in what to know about facial collagen stimulation.
Poly-D,L-lactic acid (PDLLA) intradermal boosters, sold abroad under names such as Juvelook, are sometimes called approved on the grounds that Sculptra® is. They are not: Sculptra is poly-L-lactic acid for subcutaneous volumization, a different polymer, plane and indication. No PDLLA intradermal booster carries U.S. approval.
What patients name from abroad, and what U.S. law allows
Every product below is named by patients citing Korean, U.K. or EU clinics, and none is FDA approved or cleared for injection in the United States.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
- Profhilo® cannot be lawfully marketed or injected here. It is not a BDDE-crosslinked filler but a thermally stabilized hybrid complex of high- and low-molecular-weight hyaluronic acid. In July 2026 Evolus licensed U.S. rights from IBSA and became responsible for the development work required for approval. A license is not an approval or a timeline.
- Restylane Skinboosters (Vital and Vital Light) have never been approved here. Galderma holds numerous U.S. Restylane approvals; none covers the Skinboosters line.
- Juvéderm® Volite is the ex-U.S. brand name for the same 12 mg/mL gel approved here as SKINVIVE™; the Volite name has no U.S. approval.
- Rejuran® and other polynucleotide or PDRN injectables have no U.S. approval or clearance. Empire covers the class in polynucleotides explained and on the PDRN reference page.
- Juvelook and other PDLLA injectables: no U.S. device record. Sunekos, a hyaluronic acid and amino-acid injectable: no U.S. device record, and a peer-reviewed record thin enough that efficacy claims are unsupported.
- Exosome-based “boosters.” FDA states there are no FDA-approved exosome products; exosomes for human treatment are regulated as drugs or biologics requiring premarket approval. See the current FDA posture on exosomes.
The vocabulary must be exact. Off-label means an approved product used outside its labeled indication — injecting SKINVIVE™ somewhere other than the cheeks or neck. Unapproved means no U.S. approval exists for the product at all, which is the case for every other name above: not a judgment call at the margins of a label, but outside the regulatory system entirely.
The Korea Herald reported in August 2025 that Korea received more than 1.17 million foreign patients in 2024, a 93% year-on-year rise, with dermatology’s share climbing from 35.2% to 56.6%. That is trend reporting rather than clinical evidence, but it explains the traffic.
What the pivotal trial showed, and the durability claim to avoid
The U.S. approval rested on a randomized, multicenter, evaluator-blind, no-treatment-controlled study at 14 U.S. sites. Of 255 enrolled, 209 were randomized: 135 to treatment and 73 to a delayed-treatment control. The primary endpoint was the blinded investigator’s Allergan Cheek Smoothness Scale responder rate, defined as at least a one-point improvement in both cheeks at one month. In the modified intent-to-treat population, 57.9% of treated participants responded versus 4.5% of untreated controls (p < 0.001). Durability was documented through six months, where 55.6% (69 of 124) remained responders. That is the number to quote.
Here is the trap. The widely repeated “results through nine months” and “96% response” claims are not from the U.S. pivotal trial. They come from a supportive European single-arm study of 131 participants using the product without lidocaine, in which 96.2% of treated cheeks were responders at one month, 76.3% at four months and only 15.7% at nine months. Quoting nine months without that 15.7% figure turns a decay curve into a duration claim, and 96.2% described treated cheeks in a single-arm study, not 96% of patients in a controlled one.
Superficial does not mean risk-free
The common assumption is that placing product in the dermis removes vascular risk. It does not. Barrera, Murray and Pantano published a partially reversible episode of blindness after intravascular hyaluronic acid injection in Plastic and Reconstructive Surgery Global Open (2024;12(11):e6316, PMID 39568688), presenting it explicitly as blindness related to a skin booster and noting that skin boosters are often assumed to carry no risk of visual problems. FDA’s review of SKINVIVE™ lists vascular occlusion among events reported in worldwide postmarket surveillance, alongside inflammatory reaction, inflammatory nodule, allergic reaction, infection and abscess. The label’s warnings carry the full hyaluronic acid class risks: temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis and damage to underlying facial structures.
The expected course is also noisy. In the pivotal trial, injection-site responses after initial treatment included redness in 68.8% of participants, lumps and bumps in 63.3%, bruising in 57.8% and discoloration in 34.2%. Most were mild or moderate (72.9%) and resolved within seven days, and physician-reported treatment-related adverse events were rare, at 3.0% of 199 treated participants. Consent that omits the bruising and bleb expectation is consent a patient feels misled by on day two.
Papules and nodules are the category’s characteristic aesthetic complication, and they behave worse with polymer boosters than with hyaluronic acid. Rho and colleagues report papules or nodules after superficial polymer injection, citing early intradermal poly-L-lactic acid data of non-inflammatory 2–4 mm nodules in 12 of 94 cases appearing two to nine months later, against roughly 0.4% with current protocols. The label is blunt: injecting the product too superficially may result in visible lumps and/or discoloration — the mechanism behind the bluish cast clinicians recognize as the Tyndall effect. How superficial is too superficial remains contested; Lim and colleagues titled a 2026 Journal of Cosmetic Dermatology commentary “Intradermal ‘Skin Boosters’: Are We Targeting Too Superficially?” (2026;25(5):e70906, PMID 42152513).
Frequently asked questions
What is a skin booster?
A skin booster is an injectable, usually a low-crosslinked hyaluronic acid gel, placed in small aliquots in the dermis to improve skin quality — surface evenness, fine lines, hydration and glow — rather than to add volume. Rho and colleagues note that the intradermal plane defines the class, since subdermal placement replaced fluid volume without improving texture. In the U.S., the term covers one approved product and several unapproved imports.
Are skin boosters the same as fillers?
Both are injectable gels, and the approved U.S. skin booster is regulated as a dermal filler, but the products and goals differ. Volumizing fillers are highly crosslinked, high-G′ gels placed deep to project and support tissue; boosters are lower-concentration, less crosslinked, lower-G′ gels placed intradermally to change how the surface looks. One manufacturer holds both indications under a single premarket approval, for opposite planes and endpoints.
Is SKINVIVE a skin booster?
Yes, and it is the only one with U.S. approval in this category. FDA approved SKINVIVE™ by Juvéderm® in May 2023 for intradermal injection to improve skin smoothness of the cheeks in adults over 21, and in June 2026 added a neck indication covering intradermal and/or subdermal injection to reduce neck lines. Juvéderm® Volite, sold outside the U.S., is the same gel and carries no U.S. approval.
Do skin boosters work?
For the approved product in its approved indication, the controlled evidence is positive and modest: 57.9% of treated participants met the blinded responder definition at one month versus 4.5% of untreated controls, and 55.6% were still responders at six months. That is a real effect on a smoothness scale rather than a transformation, and expectations are better set against those numbers than the 96% and nine-month figures from a single-arm European study.
Can skin boosters cause vascular occlusion?
Yes. A published case reports partially reversible blindness after intravascular hyaluronic acid injection given as a skin booster, and FDA’s review of the approved product lists vascular occlusion among events reported in worldwide postmarket surveillance. Superficial placement lowers the odds; it does not remove the mechanism, and the vascular-complication algorithm belongs in the room.
Where to learn this properly
Product selection, injection plane and complication management are what this category punishes providers for guessing at, and all three are hands-on skills. Empire’s Complete Dermal Filler Training is the hands-on dermal filler workshop for licensed clinicians who want technique built on rheology and anatomy rather than product names — the foundation to have before deciding where an intradermal skin-quality treatment belongs in your practice.
